Laboratorios Saval S.A. has acquired a pharmeceutical processing plant
Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.
Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.
Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.
Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.


Talk to the deal team
Related deals
St. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreRAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn more